The Journal of Headache and Pain is the official journal of the European Headache Federation and Lifting The Burden.
Articles
Page 8 of 64
-
Citation: The Journal of Headache and Pain 2021 22(Suppl 2):130
-
Altered static and dynamic functional network connectivity in post-traumatic headache
Post-traumatic headache (PTH) is a very common symptom following mild traumatic brain injury (mTBI), yet much remains unknown about the underlying pathophysiological mechanisms of PTH. Neuroimaging studies sug...
Citation: The Journal of Headache and Pain 2021 22:137 -
The management and clinical knowledge of headache disorders among general practitioners in Norway: a questionnaire survey
General practitioners (GPs) diagnose and manage a majority of headache patients seeking health care. With the aim to understand the potential for clinical improvement and educational needs, we performed a stud...
Citation: The Journal of Headache and Pain 2021 22:136 -
Correction to: Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study
Citation: The Journal of Headache and Pain 2021 22:135 -
Pain sensitivity in men who have never experienced a headache: an observer blinded case control study
Headache affects 90–99% of the population. Based on the question “Do you think that you never ever in your whole life have had a headache?” 4% of the population say that they have never experienced a headache....
Citation: The Journal of Headache and Pain 2021 22:134 -
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in...
Citation: The Journal of Headache and Pain 2021 22:133 -
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
Lasmiditan (LTN) is a selective 5-HT1F receptor agonist for the acute treatment of migraine in adults. We present detailed safety findings from the placebo-controlled, double-blind Phase 3 study, of LTN treatment...
Citation: The Journal of Headache and Pain 2021 22:132 -
Correction to: Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
Citation: The Journal of Headache and Pain 2021 22:131 -
Regional homogeneity alterations in multi-frequency bands in tension-type headache: a resting-state fMRI study
In this study, we aimed to investigate the spontaneous neural activity in the conventional frequency band (0.01−0.08 Hz) and two sub-frequency bands (slow-4: 0.027–0.073 Hz, and slow-5: 0.01–0.027 Hz) in tensi...
Citation: The Journal of Headache and Pain 2021 22:129 -
CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple f...
Citation: The Journal of Headache and Pain 2021 22:128 -
Differences in gray matter volume in episodic migraine patients with and without prior diagnosis or clinical care: a cross-sectional study
Migraine sufferers face difficulties getting appropriate care and treatment. Migraine is associated with reduced gray matter volume (GMV) in several brain regions, which could be related to various clinical ch...
Citation: The Journal of Headache and Pain 2021 22:127 -
Minimal important change and responsiveness of the Migraine Disability Assessment Score (MIDAS) questionnaire
The MIDAS is the most used questionnaire to evaluate migraine-related disability, but its utility to assess treatment response remains unclear. Our aim was to estimate the MIDAS’ minimal important change (MIC)...
Citation: The Journal of Headache and Pain 2021 22:126 -
Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study
To compare symptoms of clinical androgen deficiency between men with migraine, men with cluster headache and non-headache male controls.
Citation: The Journal of Headache and Pain 2021 22:125 -
Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults
Migraine has been associated with cardiovascular disease (CVD) events among middle-aged adults. The objective of this study was to determine the risk for ischemic stroke and coronary heart disease (CHD) events...
Citation: The Journal of Headache and Pain 2021 22:124 -
Understanding the link between obesity and headache- with focus on migraine and idiopathic intracranial hypertension
Obesity confers adverse effects to every system in the body including the central nervous system. Obesity is associated with both migraine and idiopathic intracranial hypertension (IIH). The mechanisms underly...
Citation: The Journal of Headache and Pain 2021 22:123 -
Angioarchitectural features amongst patients with unruptured brain arteriovenous malformations presenting with headache: findings from a single center retrospective review of 76 patients
Brain arteriovenous malformations (AVMs) consist of abnormal connections between arteries and veins via an interposing nidus. While hemorrhage is the most common presentation, unruptured AVMs can present with ...
Citation: The Journal of Headache and Pain 2021 22:122 -
Inflammatory complications of CGRP monoclonal antibodies: a case series
Calcitonin gene-related peptide (CGRP) is expressed throughout the body and is a known mediator of migraine, exerting this biological effect through activation of trigeminovascular, meningeal and associated ne...
Citation: The Journal of Headache and Pain 2021 22:121 -
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication overuse (MO), but data is limited. We evaluated their effectiveness in a real-life clinical cohort.
Citation: The Journal of Headache and Pain 2021 22:120 -
Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults
Migraine is a common neurological disease with extremely debilitating, but fully reversible symptoms. Women suffer from migraine more often than men. It was assumed that fluctuation of oestrogen level during m...
Citation: The Journal of Headache and Pain 2021 22:119 -
Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension
Headache is the predominant disabler in idiopathic intracranial hypertension (IIH). The aim was to characterise headache and investigate the association with intracranial pressure.
Citation: The Journal of Headache and Pain 2021 22:118 -
Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis
Recent data suggest that gene expression profiles of peripheral white blood cells can reflect changes in the brain. We aimed to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) and change...
Citation: The Journal of Headache and Pain 2021 22:117 -
Correction to: Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-analysis
Citation: The Journal of Headache and Pain 2021 22:116 -
Correction to: CGRP induces migraine-like symptoms in mice during both the active and inactive phases
Citation: The Journal of Headache and Pain 2021 22:115 -
Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study
Monoclonal antibodies (mABs) targeting the calcitonin gene-related peptide (CGRP) pathway represent the first disease-specific preventive migraine therapy. Growing evidence suggests that they are effective in ...
Citation: The Journal of Headache and Pain 2021 22:114 -
Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
Chronic migraine (CM) and episodic migraine (EM) are associated with substantial headache-related disability, poor quality of life and global societal burden. In this subgroup analysis from the CONQUER study, ...
Citation: The Journal of Headache and Pain 2021 22:113 -
Leveraging high-resolution 7-tesla MRI to derive quantitative metrics for the trigeminal nerve and subnuclei of limbic structures in trigeminal neuralgia
Trigeminal Neuralgia (TN) is a chronic neurological disease that is strongly associated with neurovascular compression (NVC) of the trigeminal nerve near its root entry zone. The trigeminal nerve at the site o...
Citation: The Journal of Headache and Pain 2021 22:112 -
CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience
Calcitonin gene-related peptide (CGRP) (receptor) antibodies (erenumab, fremanezumab and galcanezumab) are increasingly used in prophylactic treatment of migraine. In the approval studies, severely affected pa...
Citation: The Journal of Headache and Pain 2021 22:111 -
Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
These subgroup analyses of a Phase 3, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of erenumab 70 mg in Japanese migraine patients with/without prior preventive treatmen...
Citation: The Journal of Headache and Pain 2021 22:110 -
Osmophobia in primary headache patients: associated symptoms and response to preventive treatments
Osmophobia, is common among primary headaches, with prevalence of migraine.
Citation: The Journal of Headache and Pain 2021 22:109 -
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis
Headache is a frequent symptom following COVID-19 immunization with a typical onset within days post-vaccination. Cases of cerebral venous thrombosis (CVT) have been reported in adenovirus vector-based COVID-1...
Citation: The Journal of Headache and Pain 2021 22:108 -
Enhanced functional connectivity between habenula and salience network in medication-overuse headache complicating chronic migraine positions it within the addiction disorders: an ICA-based resting-state fMRI study
Medication-overuse headache (MOH) is a relatively frequently occurring secondary headache caused by overuse of analgesics and/or acute migraine medications. It is believed that MOH is associated with dependenc...
Citation: The Journal of Headache and Pain 2021 22:107 -
Migraine patients in Germany - need for medical recognition and new preventive treatments: results from the PANORAMA survey
Migraine is a primary headache disorder characterized by recurrent attacks that may have a significant impact on patients’ daily life. Treatment options must often be re-evaluated in light of efficacy, tolerab...
Citation: The Journal of Headache and Pain 2021 22:106 -
CGRP outflow into jugular blood and cerebrospinal fluid and permeance for CGRP of rat dura mater
Calcitonin gene-related peptide (CGRP) is released from activated meningeal afferent fibres in the cranial dura mater, which likely accompanies severe headache attacks. Increased CGRP levels have been observed...
Citation: The Journal of Headache and Pain 2021 22:105 -
The International Headache Congress – IHS and EHF joint congress 2021
Citation: The Journal of Headache and Pain 2021 22(Suppl 1):103 -
Flatness of the Meckel cave may cause primary trigeminal neuralgia: a radiomics-based study
Neurovascular contact (NVC) is the main cause of primary trigeminal neuralgia (PTN); however, cases of PTN without NVC are still observed. In this study, the Meckel cave (MC) morphology in PTN were analyzed by...
Citation: The Journal of Headache and Pain 2021 22:104 -
Disconnectome of the migraine brain: a “connectopathy” model
In the past decades a plethora of studies has been conducted to explore resting-state functional connectivity (RS-FC) of the brain networks in migraine with conflicting results probably due to the variability ...
Citation: The Journal of Headache and Pain 2021 22:102 -
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN
While pain freedom at 2 h is a key primary outcome for current trials for acute treatment of migraine, the relationship between the degree of head pain and other efficacy measures at 2 h has rarely been explor...
Citation: The Journal of Headache and Pain 2021 22:101 -
Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Citation: The Journal of Headache and Pain 2021 22:100 -
Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology
Health economic evaluations support health-care decision-making by providing information on the costs and consequences of health interventions. No universally accepted methodology exists for modelling effectiv...
Citation: The Journal of Headache and Pain 2021 22:99 -
Investigation of cortical thickness and volume during spontaneous attacks of migraine without aura: a 3-Tesla MRI study
Structural imaging has revealed changes in cortical thickness in migraine patients compared to healthy controls is reported, but presence of dynamic cortical and subcortical changes during migraine attack vers...
Citation: The Journal of Headache and Pain 2021 22:98 -
Coronavirus disease-19 and headache; impact on pre-existing and characteristics of de novo: a cross-sectional study
Coronavirus disease-19 is caused by the severe acute respiratory syndrome coronavirus 2 Headache is a common symptom during and after Coronavirus disease-19. We aimed to study headache character in relation to...
Citation: The Journal of Headache and Pain 2021 22:97 -
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education for patients with tension-type headache. A systematic review and meta-analysis
Tension-type headache (TTH) has been ranked the second most prevalent health condition worldwide. Non-pharmacological treatments for TTH are widely used as a supplement or an alternative to medical treatment. ...
Citation: The Journal of Headache and Pain 2021 22:96 -
Whole-brain morphological alterations associated with trigeminal neuralgia
Novel neuroimaging strategies have the potential to offer new insights into the mechanistic basis for trigeminal neuralgia (TN). The present study aims to conduct whole-brain morphometry analyses of TN patient...
Citation: The Journal of Headache and Pain 2021 22:95 -
HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism
Pathogenesis of COVID-19 -related headache is unknown, though the induction of the trigeminal neurons through inflammation is proposed. We aimed to investigate key systemic circulating inflammatory molecules a...
Citation: The Journal of Headache and Pain 2021 22:94 -
Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
We report the first case of a patient who suffered transient focal neurological deficit mimicking stroke following CoronaVac vaccination. However, instead of an ischemic stroke, motor aura was suspected.
Citation: The Journal of Headache and Pain 2021 22:93 -
Functional correlation of ATP1A2 mutations with phenotypic spectrum: from pure hemiplegic migraine to its variant forms
Mutations in ATP1A2, the gene encoding the α2 subunit of Na+/K+-ATPase, are the main cause of familial hemiplegic migraine type 2 (FHM2). The clinical presentation of FHM2 with mutations in the same gene varies f...
Citation: The Journal of Headache and Pain 2021 22:92 -
Regional cerebral blood flow as predictor of response to occipital nerve block in cluster headache
Cluster headache is an excruciating disorder with no cure. Greater occipital nerve blockades can transiently suppress attacks in approximately 50% of patients, however, its mechanism of action remains uncertai...
Citation: The Journal of Headache and Pain 2021 22:91 -
Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions
There have been several calls for estimations of costs and consequences of headache interventions to inform European public-health policies. In a previous paper, in the absence of universally accepted methodol...
Citation: The Journal of Headache and Pain 2021 22:90 -
Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan
Considering the involvement of genetics in migraine pathogenesis in diverse ethnic populations, genome-wide association studies (GWAS) are being conducted to identify migraine-susceptibility genes. However, li...
Citation: The Journal of Headache and Pain 2021 22:89 -
The baton changed hands
Citation: The Journal of Headache and Pain 2021 22:88
Official journal of
Annual Journal Metrics
-
2022 Citation Impact
7.4 - 2-year Impact Factor
7.1 - 5-year Impact Factor
2.002 - SNIP (Source Normalized Impact per Paper)
1.593 - SJR (SCImago Journal Rank)2022 Speed
3 days submission to first editorial decision for all manuscripts (Median)
49 days submission to accept (Median)2022 Usage
4,377,089 downloads
9,457 Altmetric mentions
- ISSN: 1129-2377 (electronic)
- ISSN: 1129-2369 (print)
Related reading
- Clinical Scales for Headache Disorders
- Headache Disorders in Pandemic Conditions
- Non-Migraine Primary Headaches in Medicine
- Migraine in Medicine
- Novel Synthetic Drugs in Migraine
- Monoclonal Antibodies in Headache
- Neurophysiology of the Migraine Brain
- Societal Impact of Headache
- Neuromodulation in Headache and Facial Pain Management
- Cluster Headache and other Trigeminal Autonomic Cephalgias
- Peripheral Interventional Management in Headache
- Placebos and Nocebos in Headaches
- Gender and Migraine
- Headache and Comorbidities in Childhood and Adolescence
- Comorbidities in Headache Disorders
- Pharmacological Management of Headaches
- Pathophysiology of Headaches